In the last year, Denmark's second-largest pharmaceutical company, Lundbeck, has upgraded its expenses for research and development, not least due to its major stakes on turning migraine drug Vyepti into a blockbuster.
Thus, Lundbeck placed more than 25 percent of its revenue in research and development investments, while the concurrent figure for Novo Nordisk was around half of that in the same time period.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.